T cells redirected to interleukin-13Rα2 with interleukin-13 mutein-chimeric antigen receptors have anti-glioma activity but alsorecognize interleukin-13Rα1

Cytotherapy

Volumn 16, Issue 8, 2014, Pages 1121-1131

  Krebs, Simone ^a,b   Chow, Kevin K H ^a,b   Yi, Zhongzhen ^a,b   Rodriguez Cruz, Tania ^a,b   Hegde, Meenakshi ^a,b   Gerken, Claudia ^a,b   Ahmed, Nabil ^a,b   Gottschalk, Stephen ^a,b  

^a CENTER FOR CELL AND GENE THERAPY   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Cancer; CAR; GBM; IL13R 1; IL13R 2; Immunotherapy; T cells

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; GAMMA INTERFERON; INTERLEUKIN 13 MUTEIN; INTERLEUKIN 13 RECEPTOR ALPHA1; INTERLEUKIN 13 RECEPTOR ALPHA2; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 4 RECEPTOR; LYMPHOCYTE ANTIGEN RECEPTOR; UNCLASSIFIED DRUG; IMMUNOTOXIN; RECOMBINANT PROTEIN;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING SITE; BIOLOGICAL ACTIVITY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOTOXICITY TEST; GLIOMA; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR RECOGNITION; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SURVIVAL RATE; T LYMPHOCYTE; ANIMAL; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; GLIOBLASTOMA; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; PATHOLOGY;

ANIMALIA;

AMINO ACID SUBSTITUTION; ANIMALS; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; IMMUNOTHERAPY; IMMUNOTOXINS; INTERLEUKIN-13 RECEPTOR ALPHA1 SUBUNIT; INTERLEUKIN-13 RECEPTOR ALPHA2 SUBUNIT; MICE; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT PROTEINS; T-LYMPHOCYTES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84903815285     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2014.02.012     Document Type: Article

References (37)

1. Okada H., Kohanbash G., Zhu X., Kastenhuber E.R., Hoji A., Ueda R., et al. Immunotherapeutic approaches for glioma. Crit Rev Immunol 2009, 29:1-42.
2. Mitchell D.A., Sampson J.H. Toward effective immunotherapy for the treatment of malignant brain tumors. Neurotherapeutics 2009, 6:527-538.
3. Chow K.K., Gottschalk S. Cellular immunotherapy for high-grade glioma. Immunotherapy 2011, 3:423-434.
4. Finocchiaro G., Pellegatta S. Immunotherapy for glioma: getting closer to the clinical arena?. Curr Opin Neurol 2011, 24:641-647.
5. Curran K.J., Pegram H.J., Brentjens R.J. Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions. JGene Med 2012, 14:405-415.
6. Ahmed N., Salsman V.S., Kew Y., Shaffer D., Powell S., Zhang Y.J., et al. HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors. Clin Cancer Res 2010, 16:474-485.
7. Chow K.K., Naik S., Kakarla S., Brawley V.S., Shaffer D.R., Yi Z., et al. Tcells redirected to EphA2 for the immunotherapy of glioblastoma. Mol Ther 2013, 21:629-637.
8. Kahlon K.S., Brown C., Cooper L.J., Raubitschek A., Forman S.J., Jensen M.C. Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells. Cancer Res 2004, 64:9160-9166.
9. Bullain S.S., Sahin A., Szentirmai O., Sanchez C., Lin N., Baratta E., et al. Genetically engineered T cells to target EGFRvIII expressing glioblastoma. JNeurooncol 2009.
10. Morgan R.A., Johnson L.A., Davis J.L., Zheng Z., Woolard K.D., Reap E.A., et al. Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma. Hum Gene Ther 2012, 23:1043-1053.
11. Kong S., Sengupta S., Tyler B., Bais A.J., Ma Q., Doucette S., et al. Suppression of human glioma xenografts with second-generation IL13R-specific chimeric antigen receptor-modified T cells. Clin Cancer Res 2012, 18:5949-5960.
12. Brentjens R.J., Riviere I., Park J.H., Davila M.L., Wang X., Stefanski J., et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 2011, 118:4817-4828.
13. Brentjens R.J., Davila M.L., Riviere I., Park J., Wang X., Cowell L.G., et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 2013, 5:177ra38.
14. Kalos M., Levine B.L., Porter D.L., Katz S., Grupp S.A., Bagg A., et al. Tcells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011, 3:95ra73.
15. Grupp S.A., Kalos M., Barrett D., Aplenc R., Porter D.L., Rheingold S.R., et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. NEngl J Med 2013, 368:1509-1518.
16. Kochenderfer J.N., Dudley M.E., Feldman S.A., Wilson W.H., Spaner D.E., Maric I., et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 2012, 119:2709-2720.
17. Brentjens R., Yeh R., Bernal Y., Riviere I., Sadelain M. Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. Mol Ther 2010, 18:666-668.
18. Morgan R.A., Yang J.C., Kitano M., Dudley M.E., Laurencot C.M., Rosenberg S.A. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 2010, 18:843-851.
19. Lamers C.H., Sleijfer S., Vulto A.G., Kruit W.H., Kliffen M., Debets R., et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. JClin Oncol 2006, 24:e20-e22.
20. Wels W., Harwerth I.M., Zwickl M., Hardman N., Groner B., Hynes N.E. Construction, bacterial expression and characterization of a bifunctional single-chain antibody-phosphatase fusion protein targeted to the human erbB-2 receptor. Biotechnology 1992, 10:1128-1132.
21. Vera J., Savoldo B., Vigouroux S., Biagi E., Pule M., Rossig C., et al. Tlymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. Blood 2006, 108:3890-3897.
22. Pule M.A., Straathof K.C., Dotti G., Heslop H.E., Rooney C.M., Brenner M.K. Achimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol Ther 2005, 12:933-941.
23. Kakarla S., Chow K.K., Mata M., Shaffer D.R., Song X.T., Wu M.F., et al. Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma. Mol Ther 2013.
24. Gottschalk S., Edwards O.L., Sili U., Huls M.H., Goltsova T., Davis A.R., et al. Generating CTL against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive Immunotherapy of EBV-associated malignancies. Blood 2003, 101:1905-1912.
25. Nguyen V., Conyers J.M., Zhu D., Gibo D.M., Dorsey J.F., Debinski W., et al. IL-13Ralpha2-targeted therapy escapees: biologic and therapeutic implications. Transl Oncol 2011, 4:390-400.
26. Iwami K., Shimato S., Ohno M., Okada H., Nakahara N., Sato Y., et al. Peptide-pulsed dendritic cell vaccination targeting interleukin-13 receptor alpha2 chain in recurrent malignant glioma patients with HLA-A*24/A*02 allele. Cytotherapy 2012.
27. Brown C.E., Starr R., Naranjo A., Wright C., Bading J., Ressler J., et al. Adoptive transfer of autologous IL13-zetakine+ engineered T cell clones for the treatment of recurrent glioblastoma: lessons from the clinic. Mol Ther 2011, 19:S136-S137.
28. Kunwar S., Prados M.D., Chang S.M., Berger M.S., Lang F.F., Piepmeier J.M., et al. Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. JClin Oncol 2007, 25:837-844.
29. Nash K.T., Thompson J.P., Debinski W. Molecular targeting of malignant gliomas with novel multiply-mutated interleukin 13-based cytotoxins. Crit Rev Oncol Hematol 2001, 39:87-98.
30. Madhankumar A.B., Mintz A., Debinski W. Interleukin 13 mutants of enhanced avidity toward the glioma-associated receptor, IL13Ralpha2. Neoplasia 2004, 6:15-22.
31. Debinski W., Thompson J.P. Retargeting interleukin 13 for radioimmunodetection and radioimmunotherapy of human high-grade gliomas. Clin Cancer Res 1999, 5:3143s-3147s.
32. Thompson J.P., Debinski W. Mutants of interleukin 13 with altered reactivity toward interleukin 13 receptors. JBiol Chem 1999, 274:29944-29950.
33. Hudecek M., Lupo-Stanghellini M.T., Kosasih P.L., Sommermeyer D., Jensen M., Rader C., et al. Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T-cells. Clin Cancer Res 2013.
34. Kioi M., Seetharam S., Puri R.K. Targeting IL-13Ralpha2-positive cancer with a novel recombinant immunotoxin composed of a single-chain antibody and mutated Pseudomonas exotoxin. Mol Cancer Ther 2008, 7:1579-1587.
35. Balyasnikova I.V., Wainwright D.A., Solomaha E., Lee G., Han Y., Thaci B., et al. Characterization and immunotherapeutic implications for a novel antibody targeting interleukin (IL)-13 receptor alpha2. JBiol Chem 2012, 287:30215-30227.
36. Milone M.C., Fish J.D., Carpenito C., Carroll R.G., Binder G.K., Teachey D., et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther 2009, 17:1453-1464.
37. Hegde M., Corder A., Chow K.K., Mukherjee M., Ashoori A., Kew Y., et al. Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma. Mol Ther 2013, 21:2087-2101.